W911QY20C0100

Dec 2020: ModernaUS Inc., Cambridge, Massachusetts, was awarded a $1,966,598,000 modification (P00003) to contract W911QY20C0100 for purchase of an additional 100 million filled drug production doses of SARS-CoV-2 mRNA-1273 vaccine utilizing Option 1 and acetate efforts on the base and option. Work will be performed in Cambridge, Massachusetts, with an estimated completion date of June 30, 2021. Fiscal 2021 research, development, test and evaluation funds in the amount of $1,966,598,000 were obligated at the time of the award.  U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity. (Awarded Dec. 11, 2020)

Feb 2021: Moderna US, Cambridge, Massachusetts, was awarded a $1,650,000,000 modification (P00004) to contract W911QY-20-C-0100 for an additional 100 million doses of SARS-CoV-2 mRNA-1273 Moderna vaccine.  Work will be performed in Cambridge, Massachusetts, with an estimated completion date of July 31, 2021.  Fiscal 2021 research, development, test and evaluation (Army) funds in the amount of $1,650,000,000 were obligated at the time of the award.  U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity. (Awarded Feb. 11, 2021)

Jun 2021: ModernaTX Inc.,* Cambridge, Massachusetts, was awarded a $3,300,000,000 modification (P00007) to contract W911QY-20-C-0100 for 200 million filled drug production doses of SARS-CoV-2 mRNA-1273 Moderna vaccine.  Work will be performed in Cambridge, Massachusetts, with an estimated completion date of March 31, 2022.  Fiscal 2010 research, development, test and evaluation (Army) funds in the amount of $3,300,000,000 were obligated at the time of the award.  U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity. (Awarded June 15, 2021)

Mar 2022: ModernaTX Inc.,* Cambridge, Massachusetts, was awarded a $26,000,000 modification (P00022) to contract W911QY-20-C-0100 for a change to the production schedule of COVID-19 vaccine to a different presentation/type. Work will be performed in Cambridge, Massachusetts, with an estimated completion date of March June 30, 2022. Coronavirus Response Relief Supplemental Appropriations Act funds in the amount of $26,000,000 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity. (Awarded March 28, 2022)

Apr 2022: ModernaTX Inc., Cambridge, Massachusetts, was awarded a $10,500,000 modification (P00023) to contract W911QY-20-C-0100 for a change to the production schedule from one presentation/type of COVID-19 vaccine to a different presentation/type. Work will be performed in Cambridge, Massachusetts, with an estimated completion date of June 30, 2022. Coronavirus Response and Relief Supplemental Appropriations funds in the amount of $10,500,000 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity. (Awarded April 14, 2022)

Aug 2022: ModernaTX Inc., Cambridge, Massachusetts, was awarded a $17,477,343 modification (PZ0025) to contract W911QY-20-C-0100 for pediatric primary series vaccines. Work will be performed in Cambridge, Massachusetts, with an estimated completion date of June 30, 2023. Fiscal 2021 Coronavirus Response and Relief Supplemental Appropriations Act funds in the amount of $17,477,343 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity.